YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF vs Zoetis Inc — how do they compare? YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $38.55, while Zoetis Inc trades at $73.91 (market cap $30.40B). The key difference: Zoetis Inc pays a 2.88% dividend while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF pays none, and YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| QDTY | ZTS | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $46.71 | $150.61 |
52-Week Low | $36.57 | $71.91 |
Market Cap | — | $30.40B |
Enterprise Value | — | $37.96B |
Dividend Yield | — | 2.88% |
Signals from Pluang's Aura AI — not financial advice
QDTY trades at $39.07, up 0.12% on the day, with a bearish technical signal driven by moving averages. The stock exhibits weekly dividend distributions, yet key valuation and profitability ratios are unavailable, limiting fundamental clarity. Recent news highlights consistent dividend announcements from YieldMax ETFs, indicating a focus on income generation.
The outlook hinges on forthcoming financial disclosures to assess sustainability; risks include reliance on dividend strategy amid missing fundamentals. Investors face uncertainty without earnings or revenue data, requiring caution until corporate performance metrics are published.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Trailing returns across standard periods
Latest headlines on both assets
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →